Clinical efficacy observation of GnRH-α and gestrinone in consolidation therapy after operation of endometriosis

Objective To observe the clinical efficacy of GnRH-α and gestrinone in consolidation therapy after operation of endometriosis. Methods Eighty cases undergoing conservative surgery and diagnosed as pelvic endometriosis by pathological examination from January 2005 to January 2008 were divided into 2 groups randomly. 45 cases in GnRH- α group were injected GnRH -α 3.75 mg each time per 28 days from the first -fifth day of menstruation. 35 cases in gestrinone group took gestrinone 2.5 mg per day, twice a week from the first day of menstruation. Results The rates of dysmenorrhea and other painful systems in two groups after treatment were significantly lower than those before treatment (P 0.05). Followed up results showed that complete remission rates in GnRH-α group and gestrinone group were 88.9% and 85.7%, respectively. The relapse rates in GnRH-α group and gestrinone group were 4.4% and 5.7%, respectively. There was no significant difference ( P 0.05). The incidence of adverse reaction in GnRH- α group was significantly lower than that in gestrinone group. Conclusion Application of GnRH-α and gestrinone in consolidation therapy after operation of endometriosis is safe and effective, without serve adverse reactions.